Standard BioTools (LAB) EV/EBITDA Multiple
Standard BioTools Inc. (LAB) historical EV/EBITDA level correlates with the R&D budgets of pharma behemoths and government support for precision medicine, with the metric holding around 0.00. Standard BioTools Inc. (LAB) attracts scientists through its innovative approach to genomics and mass cytometry. The business stability is ensured by proprietary cell analysis solutions that are difficult to replace in laboratory processes.
Analytical breakdowns for fluidigm.com (LAB)
- market price and analyst price targets:
- market capitalization details:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Equity Ratio Standard BioTools Inc.|LAB - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Standard BioTools|LAB - Company Aggregate Debts|Debt to Book Capitalization Ratio Standard BioTools Corp|LAB - Company Long-Term Indebtedness|Company Short-Term Debts Standard BioTools|Quick Ratio fluidigm.com
- business earnings and investment ratios data:
LAB - Net Profit|Expected Profit Standard BioTools Inc.|LAB - Company Value to Net Income|Forward P/E Multiple Standard BioTools Inc.|LAB - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio Standard BioTools Corp|LAB - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Standard BioTools|LAB - Earnings per share for the last twelve months|Quarterly EPS earnings growth fluidigm.com|LAB - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Standard BioTools Inc.
Fundamental company analysis:LAB (Fluidigm)
The stability of Standard BioTools Inc. (LAB) relies on demand for complex mass cytometry and genomic analysis systems, making it critical to monitor the ratio of enterprise value to operating profit. This coefficient determines the real price of the asset relative to its ability to generate cash flow; therefore, the company's historical EV/EBITDA trend helps identify the balance between investment attractiveness and risks in the event of declining revenues.
Competitor analysis for Standard BioTools Inc.
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Agilent Tech A|Total Company Value to Operating Income Before Depreciation Ratio Quest Corp (DGX)|Illumina, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio exactsciences.com EXAS|Revvity (RVTY) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|BIO - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Anbio Tech|Nordion (SHC) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio QDEL (QuidelOrtho)|Enterprise Value to Operating Income Before Depreciation Ratio OPK|EV/EBITDA Multiple CDNA (CareDx Inc)|EV/EBITDA Multiple Maravai LifeSciences Holdings MRVI|FLGT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CTKB (Cytek Corp) - Enterprise Value to Operating Income Before Depreciation|OSUR: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation XGN|MDXH (MDxHealth) - EV/EBITDA Multiple|EV/EBITDA Multiple Lucid Diagnostics, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Prenetics Global (PRE)|IMDX (imdxinc.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TRIB (Trinity Biotech)|PRPH: Enterprise Value to Operating Income Before Depreciation|AIMD: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation CODX (Co-Diagnostics Inc)|HSCS: EV/EBITDA Multiple|BMRA (Biomerica Inc) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CDIO (Cardio Diagnostics Holdings Inc.) - EV/EBITDA Multiple|onconetix.gcs-web.com (ONCO) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Virax Biolabs (VRAX)|BJDX - Company Value to EBITDA|Vermillion - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio AXDX (Accelerate Diagnostics Inc)|CNTG - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Enzo Biochem, Inc.|fresh2.co (FRES) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Genetic Technologies Limited (GENE)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 23andMe Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PMD
